Eli Lilly and Co
WeightWatchers CEO just sent an internal memo to employees as stock crashes, amid debt concerns, Oprah exit
Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster than expected. […]
Read More
Experts hesitate on weight loss ETFs amid the obesity drug boom
There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of two […]
Read More
Eli Lilly taps Amazon Pharmacy to help deliver weight loss drug Zepbound, other medicines to patients
Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. Smith Collection | Gado | Getty Images Eli Lilly on Wednesday said Amazon Pharmacy will help send certain prescription drugs, including the red-hot weight loss treatment Zepbound, to patients’ homes through the drugmaker’s new direct-to-consumer program. Starting Wednesday, […]
Read More
Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The Food and Drug Administration approved Novo Nordisk‘s blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart disease, the […]
Read More
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty […]
Read More
Cigna launches effort to cap employer insurance plan spending on weight loss drugs
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Cigna on Thursday unveiled a new effort to expand insurance coverage for weight loss drugs by limiting how much health plans and employers spend on the highly popular treatments each year. […]
Read More
Novo Nordisk shares soar 5% on promising fat reduction demo final results Eli Lilly dips
Jonathan Raa | Nurphoto | Getty Photos Novo Nordisk shares climbed 5% on Thursday early morning, in accordance to LSEG details, hitting a fresh new record highs right after the Danish pharmaceutical big claimed positive early demo data for a new experimental fat loss drug. The company told an investor assembly that the Section I […]
Read More
Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial
This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim, eastern France. Sebastien Bozon | Afp | Getty Images Novo Nordisk‘s blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released […]
Read More
Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
Cr | Istock | Getty Images Biotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the end […]
Read More
Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Inflation relief: The stock market was […]
Read More